CRISPR Therapeutics (CRSP) Announces $325M Common Share Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall as megacap tech drags; Iran developments watched
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
CRISPR Therapeutics (CRSP) Prices 6.428M Share Common Offering at $70/Sh
July 1, 2020 5:53 AM EDTCRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, today announced the pricing of an underwritten public offering of 6,428,572 common shares at a public offering price of $70.00 per share. In addition, the underwriters have a 30-day... More
Piper Sandler Reiterates Bullish View on CRISPR Therapeutics (CRSP) Amid New Manufacturing Facility
June 29, 2020 8:59 AM EDTPiper Sandler analyst Edward Tenthoff reiterated an Overweight rating and $104.00 price target on CRISPR Therapeutics (NASDAQ: CRSP) citing a new manufacturing facility to produce cell therapies for clinical and commercial use, the hiring of up to 100 more full-time employees, Car-T advancing, and AACR II showing superior features of Allo Car-T Pipeline.
The... More
CRISPR Therapeutics (CRSP) Announces the Build-Out of New Cell Therapy Manufacturing Facility
June 25, 2020 8:08 AM EDTCRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that it is building a new cell therapy manufacturing facility in Framingham, Massachusetts for clinical and commercial production of the Companys investigational cell therapy product... More
